Clinical Trials Sponsored by LipoScience, Inc.

Total 36023 results

Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Trial to Compare the Efficacy and Safety Of MW05 and PEG-rhG-CSF

Breast Cancer Female

China
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC664 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics

Healthy

United States
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Safety and Efficacy of 9MW0813 in Subjects With Diabetic Macular Edema

Diabetic Macular Edema

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Nasopharyngeal Carcinoma | Gastric Adenocarcinoma | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)

Advanced Hepatocellular Carcinoma (HCC)

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

The Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With NSCLC Treated With JS001

NSCLC

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery

Mucosal Melanoma

China
Implicit Bioscience
Massachusetts General Hospital

No longer available

IC14 for ALS Patients Expanded Access (EAP)

Amyotrophic Lateral Sclerosis

United States
Shanghai Junshi Bioscience Co., Ltd.

Completed

Study of JS001 in Participants With Advanced Solid Tumors

Solid Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Unknown

Safety and Tolerability of Recombinant Humanized Anti-PD-1 Monoclonal Antibody Toripalimab for Patients With Advanced Solid Tumors

Melanoma | Urological Cancer

China
Guangzhou Henovcom Bioscience Co. Ltd.

Completed

A Study of HNC042 in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics.

Healthy

United States
Light Chain Bioscience - Novimmune SA

Completed

Study of an Anti-TLR4 mAb in Rheumatoid Arthritis

Rheumatoid Arthritis

Serbia, Bosnia and Herzegovina, Bulgaria, Georgia, Hungary, Moldova, Republic of, Poland
Biofrontera Bioscience GmbH
Accovion GmbH

Completed

Evaluation of Safety and Efficacy of BF-200 ALA for the Treatment of Actinic Keratosis With Photodynamic Therapy

Actinic Keratosis
Blaze Bioscience Australia Pty Ltd

Completed

Safety Study of a Fluorescent Marker to Visualize Cancer Cells

Skin Neoplasms

Australia
Light Chain Bioscience - Novimmune SA

Completed

First in Human Study of an Anti-Toll-like Receptor 4 (TLR4) Monoclonal Antibody (NI-0101) in Adult Healthy Volunteers (NI-0101-01)

Healthy Volunteers

Netherlands
Sygnis Bioscience GmbH & Co KG

Completed

AXIS 2: AX200 for the Treatment of Ischemic Stroke (AXIS-2)

Acute Ischemic Stroke

Spain, Belgium, Germany, Slovakia, Austria, Czech Republic, Poland
Kuros Biosurgery AG
Baxter BioScience

Completed

Safety and Efficacy of I-020502 in Meshed Skin Autografting

Burns

Germany
Light Chain Bioscience - Novimmune SA

Completed

NI-0401 in Active Crohn's Disease

Moderate to Severe Crohn's Disease
Nordic Bioscience A/S
Novartis

Completed

SMC021A - Absorption, Efficacy and Tolerance in Patients With Osteoarthritis. A Placebo-Controlled 14-Days Study

Osteoarthritis

Denmark
Nordic Bioscience A/S
Novartis

Completed

Pharmacokinetics/Pharmacodynamics of Oral Salmon Calcitonin in Patients With Osteoarthritis

Osteoarthritis

Denmark
Eli Lilly and Company
Shanghai Junshi Bioscience Co., Ltd.; AbCellera Biologics Inc.

Completed

A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)

COVID-19

United States
Meridian Bioscience, Inc.
Virginia Commonwealth University; Asian Institute of Gastroenterology, Hyderabad...

Completed

BreathID® Test: A Non-invasive Modality to Detect Pancreatic Exocrine Insufficiency

Healthy Volunteers | Chronic Pancreatitis

India
EMD Serono Research & Development Institute, Inc.
Nordic Bioscience A/S

Completed

A Study to Investigate the Safety and Effectiveness of Different Doses of Sprifermin in Participants With Osteoarthritis of the Knee (FORWARD)

Osteoarthritis, Knee

Estonia, Romania, Hong Kong, Czechia, Denmark, Poland, Argentina, United States
Shanghai Best-Link Bioscience, LLC

Recruiting

A Phase I Study to Assess the Safety and Tolerability of BL0006 for Patients With Advanced Solid Tumours

Advanced Solid Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

9MW2821 Combined With Toripalimab Injection in Subjects With Local Advanced or Metastatic Urothelial Cancer

Advanced Urothelial Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of JS401

Hyperlipidemia

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects

Idiopathic Pulmonary Fibrosis

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Clinical Study to Evaluate the Safety and Tolerability of JS001sc in Advanced Nasopharyngeal Carcinoma

Advanced Nasopharyngeal Carcinoma

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Advanced Lung Cancer

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Not yet recruiting

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Advanced Lung Cancer
Dasman Diabetes Institute
Kappa Bioscience

Recruiting

Vitamin K2 and Muscle Weakness in Type 2 Diabetes (SARK2)

Diabete Type 2

Kuwait
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

Glumetinib Combined With Toripalimab in the Treatment of Relapsed or Metastatic Non-small Cell Lung Cancer. (CT32)

Relapsed or Metastatic Non-small Cell Lung Cancer

China
Shanghai Junshi Bioscience Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Toripalimab Injection in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers

Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Phase I Clinical Study of JS004 in Subjects With Recurrent/Refractory Malignant Lymphoma of China

Recurrent/Refractory Malignant Lymphoma

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Toripalimab or Placebo With Paclitaxel and Cisplatin in Esophageal Squamous Cell Carcinoma (JUPITER06)

Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of JS002 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH).

Heterozygous Familial Hypercholesterolemia

China
Shanghai Junshi Bioscience Co., Ltd.

Terminated

Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW031 in PMO Subjects

Osteoporosis, Postmenopausal

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC

Advanced Hepatocellular Carcinoma (HCC)

Italy, Poland, Singapore, United States, China, Ukraine
Loughborough University
entrinsic bioscience LLC

Active, not recruiting

A Comparison of Three Commercial Oral Rehydration Solutions Consumed After Extra-cellular Dehydration

Fluid Balance Outcomes

United Kingdom
Shanghai Junshi Bioscience Co., Ltd.

Withdrawn

A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies

Primary Condition: Advanced Tumors

China
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection (JUPITER 04)

Hepatocellular Carcinoma

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors

Bone Metastases

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of Toripalimab or Placebo Combined With Chemotherapy in Treatment-naive Advanced NSCLC

Treatment-naive Advanced Non-small Cell Lung Cancer

China
Biofrontera Bioscience GmbH
Accovion GmbH

Completed

Safety and Efficacy Study for the Treatment of Non-Aggressive Basal Cell Carcinoma With Photodynamic Therapy

Basal Cell Carcinoma (BCC)

Germany
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal Cancer

Recurrent or Metastatic NPC

China, Taiwan, Singapore
Shanghai Junshi Bioscience Co., Ltd.

Active, not recruiting

To Evaluate the Efficacy and Safety of JS002 in HoFH Patients

Hyperlipemia

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Completed

Comparing of the Pharmacokinetic, Pharmacodynamic, Safety and Immunogenicity of MW032 and Xgeva® in Healthy Adults (MW032)

Bone Tumor

China
Mabwell (Shanghai) Bioscience Co., Ltd.

Unknown

Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid Tumors

Advanced Solid Tumor

China
Shanghai Junshi Bioscience Co., Ltd.

Completed

Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma

Malignant Lymphoma

China

Clinical Trials Sponsored by LipoScience, Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Gambia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations